<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914184</url>
  </required_header>
  <id_info>
    <org_study_id>115461</org_study_id>
    <secondary_id>2016-000598-19</secondary_id>
    <nct_id>NCT02914184</nct_id>
  </id_info>
  <brief_title>Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks</brief_title>
  <official_title>Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical consistency of three production lots of
      the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus
      (HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to
      the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity,
      reactogenicity and safety when administered as a two-dose vaccination in healthy infants
      starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled,
           multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B).

        -  Duration of the study: The intended duration of the study, per subject, will be
           approximately 7-8 months including the 6 months of extended safety follow-up period
           after the last dose of HRV vaccine.

             -  Epoch 001: Primary starting at Visit 1 (Day 0) and ending at the safety follow-up
                contact (Month 7-8).

        -  Primary completion Date (PCD): Visit 3 (Month 2-4).

        -  End of Study (EoS): Last testing results released of samples collected at Visit 3 or
           Last Subject Last Visit (LSLV) (Follow up contact at month 7-8).

        -  Study Groups:

             -  PCV-free HRV liquid formulation lot A (also referred to as Liq_A Group)

             -  PCV-free HRV liquid formulation lot B (also referred to as Liq_B Group)

             -  PCV-free HRV liquid formulation lot C (also referred to as Liq_C Group)

             -  GSK Biologicals' currently licensed lyophilised HRV formulation (also referred to
                as Lyo Group)

        -  Control:active control-GSK Biologicals' currently licensed lyophilised HRV vaccine

        -  Vaccination schedule: Two doses of HRV vaccine to be administered according to a 0, 1-2
           month schedule according to the immunisation schedule for RV vaccine.

      Note that as a result of internal change in data standards terminology, the study data
      collected was converted to cDISC and the statistical analysis plan was amended accordingly.
      &quot;Day 0&quot; in the study design was replaced by &quot;Day 1&quot;; consequently, &quot;Day n&quot; was replaced by
      &quot;Day n+1&quot;. Thus, the time frames (Day 0, Day n) of Outcome Measures described in this study
      record are different to that denoted in the full protocol document posted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">November 26, 2018</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C)</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Antibody concentrations against Rota Virus (RV) were determined as Geometric Mean Antibody Concentration (GMC) and expressed as Units per milliliter (U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value in Porcine Circovirus (PCV) -Free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Control Group</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of seroconversion rates of 1-2 months after Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL in Porcine Circovirus (PCV)-Free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
The analysis was assessed to demonstrate the immunogenicity of PCV-free liquid HRV vaccine as compared to the currently licensed lyophilised HRV vaccine (individual HRV liquid groups) in terms of seroconversion rates 1-2 months after Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Lyophilised Control Group</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of antibody concentrations at 1-2 months after Dose 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL. The analysis was assessed to demonstrate the immunogenicity of the PCV-free liquid HRV vaccine (individual HRV liquid groups) to that of the currently licensed lyophilised HRV vaccine in terms of serum anti-RV IgA antibody concentrations 1-2 months after Dose 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Anti-RV IgA Concentrations (Pooled HRV Liquid Group)</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the pooled HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunogenicity of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL, 1-2 months after Dose 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Anti-RV IgA Concentrations (Individual HRV Liquid Groups)</measure>
    <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
    <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the individual HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. The analysis was performed to assess the immunogenicity of the PCV-free liquid HRV vaccine (pooled HRV liquid groups) and the currently licensed lyophilised HRV vaccine, in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL 1-2 months after Dose 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Solicited General Adverse Events (AEs).</measure>
    <time_frame>During the 8 days (Day 1 to Day 8) follow-up period after each dose of HRV vaccine</time_frame>
    <description>Assessed solicited general AEs were cough/runny nose, diarrhea, fever (defined as temperature ≥ 38.0°C), irritability/fussiness, loss of appetite and vomiting. Any solicited general AE is defined as any occurrence of the specified symptom, irrespective of intensity grade and relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Unsolicited AEs.</measure>
    <time_frame>During the 31 day (Day 1 to Day 31) follow-up period after HRV vaccination across doses</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (Day 1 to Month 7-8)</time_frame>
    <description>SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1612</enrollment>
  <condition>Infections, Rotavirus</condition>
  <condition>Rotavirus Vaccines</condition>
  <arm_group>
    <arm_group_label>Liq_A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liq_B Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liq_C Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HRV PCV-free liquid vaccine</intervention_name>
    <description>Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally</description>
    <arm_group_label>Liq_A Group</arm_group_label>
    <arm_group_label>Liq_B Group</arm_group_label>
    <arm_group_label>Liq_C Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotarix</intervention_name>
    <description>Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally</description>
    <arm_group_label>Lyo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects' parent(s)/LAR(s) who, in the opinion of the investigator can and will comply
             with the requirements of the protocol.

          -  Written informed consent obtained from the parent(s)/LAR(s) (Legally acceptable
             representatives) of the subject prior to performing any study specific procedure.

          -  A male or female infant between, and including, 6 and 12 weeks (42-90 days) of age at
             the time of the first study vaccination.

          -  Born full-term (i.e., between a gestation period of 37 weeks 0 days and 41 weeks 6
             days).

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Child in care

          -  Use of any investigational or non-registered product other than the study vaccines
             during the period starting 30 days before the first dose of study vaccines (Day-29 to
             Day 0), or planned use during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth. For corticosteroids, this will mean prednisone (0.5 mg/kg/day, or equivalent).
             Inhaled and topical steroids are allowed.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Administration of long-acting immune-modifying drugs at any time during the study
             period.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             in the period starting 30 days before the first dose of vaccine administration and
             ending at Visit 3, with the exception of the inactivated influenza vaccine, which is
             allowed at any time during the study and other licensed routine childhood
             vaccinations.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational vaccine/product.

          -  Uncorrected congenital malformation of the gastrointestinal tract that would
             predispose for Intussusception (IS).

          -  History of IS.

          -  Family history of congenital or hereditary immunodeficiency.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Major congenital defects or serious chronic illness.

          -  Previous vaccination against RV.

          -  Previous confirmed occurrence of RVGE.

          -  GE within 7 days preceding the study vaccine administration.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  Hypersensitivity to latex.

          -  Acute disease and/or fever at the time of enrolment.

               -  Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for
                  measuring temperature in this study will be the oral cavity, the axilla and the
                  rectum.

               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
                  infection) without fever may be enrolled at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheraw</city>
        <state>South Carolina</state>
        <zip>29520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29456-9170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>Utah</state>
        <zip>84075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>San José</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San José</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauberbischofsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>97941</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schoenau Am Koenigssee</city>
        <state>Bayern</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>274-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>299-4503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>350-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>360-0846</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>146-0095</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>167-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>190-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gangwon-do</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggido</city>
        <zip>442723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>01450</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>04619</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antequera/Málaga</city>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castellón</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castellón</city>
        <zip>12530</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marbella</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hsinchu</city>
        <zip>300</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Salamanca de la Cueva I, Pahud B, Huang LM, Leonardi M, Garcia-Sicilia J, Céspedes J, Abdelnour A, Tamura T, Kuroki H, Chiu NC, Virta M, Kokko S, Horn M, Panzer F, Kim JH, Jin L, Moerman L, Debacq C, Parra J, Ugarte A, Bi D; Rota-081 Study Group. Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial. J Infect Dis. 2020 May 4. pii: jiaa210. doi: 10.1093/infdis/jiaa210. [Epub ahead of print]</citation>
    <PMID>32365189</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>June 26, 2019</results_first_submitted>
  <results_first_submitted_qc>September 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Healthy infants</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Human Rotavirus (HRV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/Posting.aspx?ID=20392</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02914184/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02914184/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 66 centers in 8 countries: 2 in Costa Rica, 10 in Finland, 6 in Germany, 7 in Japan, 6 in Republic of Korea, 9 in Spain, 6 in Taiwan and 20 in the United States (US).</recruitment_details>
      <pre_assignment_details>Among 1612 subjects enrolled in the study, 1600 were vaccinated and 1545 completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liq_A Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="P2">
          <title>Liq_B Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="P3">
          <title>Liq_C Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="P4">
          <title>Lyo Control Group</title>
          <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="396"/>
                <participants group_id="P3" count="402"/>
                <participants group_id="P4" count="402"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="386"/>
                <participants group_id="P2" count="383"/>
                <participants group_id="P3" count="385"/>
                <participants group_id="P4" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from the study area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liq_A Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="B2">
          <title>Liq_B Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="B3">
          <title>Liq_C Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="B4">
          <title>Lyo Control Group</title>
          <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="400"/>
            <count group_id="B2" value="396"/>
            <count group_id="B3" value="402"/>
            <count group_id="B4" value="402"/>
            <count group_id="B5" value="1600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" spread="1.5"/>
                    <measurement group_id="B2" value="8.3" spread="1.5"/>
                    <measurement group_id="B3" value="8.4" spread="1.6"/>
                    <measurement group_id="B4" value="8.5" spread="1.5"/>
                    <measurement group_id="B5" value="8.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="205"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="814"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="199"/>
                    <measurement group_id="B5" value="786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian Or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="263"/>
                    <measurement group_id="B2" value="258"/>
                    <measurement group_id="B3" value="262"/>
                    <measurement group_id="B4" value="262"/>
                    <measurement group_id="B5" value="1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C)</title>
        <description>Antibody concentrations against Rota Virus (RV) were determined as Geometric Mean Antibody Concentration (GMC) and expressed as Units per milliliter (U/mL).</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the Per-protocol analysis set (PPS) for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Rota Virus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations in the Human Rotavirus (HRV) Liquid Formulation Groups (Liq_A, Liq_B and Liq_C)</title>
          <description>Antibody concentrations against Rota Virus (RV) were determined as Geometric Mean Antibody Concentration (GMC) and expressed as Units per milliliter (U/mL).</description>
          <population>The analysis was performed on the Per-protocol analysis set (PPS) for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.7" lower_limit="125.6" upper_limit="193.1"/>
                    <measurement group_id="O2" value="147.3" lower_limit="118.4" upper_limit="183.3"/>
                    <measurement group_id="O3" value="175.9" lower_limit="142.8" upper_limit="216.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio of Anti-RV IgA antibody for Liq_A and Liq_B groups was calculated using ANOVA model with vaccine groups and country as fixed effects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The two-sided 95% CIs for the ratio of anti RV IgA antibody GMCs should be within the [0.5; 2] clinical limit interval.</non_inferiority_desc>
            <param_type>GMC Ratio at At Month 2-4</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio of Anti-RV IgA antibody for Liq_A and Liq_C groups was calculated using ANOVA model with vaccine groups and country as fixed effects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The two-sided 95% CIs for the ratio of anti RV IgA antibody GMCs should be within the [0.5; 2] clinical limit interval.</non_inferiority_desc>
            <param_type>GMC Ratio at At Month 2-4</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMC Ratio of Anti-RV IgA antibody for Liq_B and Liq_C groups was calculated using ANOVA model with vaccine groups and country as fixed effects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The two-sided 95% CIs for the ratio of anti RV IgA antibody GMCs should be within the [0.5; 2] clinical limit interval.</non_inferiority_desc>
            <param_type>GMC Ratio at At Month 2-4</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value in Porcine Circovirus (PCV) -Free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Control Group</title>
        <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of seroconversion rates of 1-2 months after Dose 2.</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_Pool Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of pooled lot A, B and C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value in Porcine Circovirus (PCV) -Free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Control Group</title>
          <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of seroconversion rates of 1-2 months after Dose 2.</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="76.6" upper_limit="81.8"/>
                    <measurement group_id="O2" value="81.8" lower_limit="77.2" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of Liq_Pool group compared to Lyo Control group in terms of difference in % of subjects with anti-RV IgA titer ≥ specified cut off with its 2-sided 95% CI in initially seronegative subjects</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower limit (LL) of the two-sided asymptotic standardized 95% CI for the difference in SCR for antibodies to rota virus at month 2-4 between the Liq_Pool group and Lyo Control group should be ≥ -10%.</non_inferiority_desc>
            <param_type>SCR difference at Month 2-4</param_type>
            <param_value>-2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.15</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL in Porcine Circovirus (PCV)-Free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</title>
        <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
The analysis was assessed to demonstrate the immunogenicity of PCV-free liquid HRV vaccine as compared to the currently licensed lyophilised HRV vaccine (individual HRV liquid groups) in terms of seroconversion rates 1-2 months after Dose 2.</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL in Porcine Circovirus (PCV)-Free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</title>
          <description>Seroconversion rate (SCR) was defined as the percentage of subjects who were initially seronegative (i.e., with anti-RV IgA antibody concentration less than (&lt;) 20 U/mL before the first dose of HRV vaccine) and developed anti-RV IgA antibody concentration greater than or equal to (≥) 20 U/mL at Month 2-4 (1-2 months after dose 2). SCR was analysed using Enzyme Linked Immunosorbent Assay (ELISA).
The analysis was assessed to demonstrate the immunogenicity of PCV-free liquid HRV vaccine as compared to the currently licensed lyophilised HRV vaccine (individual HRV liquid groups) in terms of seroconversion rates 1-2 months after Dose 2.</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="326"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" lower_limit="72.8" upper_limit="82.1"/>
                    <measurement group_id="O2" value="77.6" lower_limit="72.7" upper_limit="82.0"/>
                    <measurement group_id="O3" value="82.5" lower_limit="77.9" upper_limit="86.5"/>
                    <measurement group_id="O4" value="81.8" lower_limit="77.2" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Lyophilised Control Group</title>
        <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of antibody concentrations at 1-2 months after Dose 2.</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_Pool Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of pooled lot A, B and C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Pooled HRV Liquid Group) and Lyophilised Control Group</title>
          <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunological non-inferiority of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of antibody concentrations at 1-2 months after Dose 2.</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" lower_limit="140.7" upper_limit="180.1"/>
                    <measurement group_id="O2" value="153.8" lower_limit="125.1" upper_limit="189.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of Liq_Pool Group as compared to Lyo Control group in terms of the GMC ratio calculated using ANOVA model with vaccine groups and country as fixed effects</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>LL of the two-sided 95% CI for the ratio of anti-RV IgA antibody GMCs between the Liq_Pool Group and Control group should be ≥ 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio at At Month 2-4</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</title>
        <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL. The analysis was assessed to demonstrate the immunogenicity of the PCV-free liquid HRV vaccine (individual HRV liquid groups) to that of the currently licensed lyophilised HRV vaccine in terms of serum anti-RV IgA antibody concentrations 1-2 months after Dose 2.</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-RV IgA Antibody Concentrations in the PCV-free Liquid HRV Vaccine (Individual HRV Liquid Groups) and Lyophilised Control Group</title>
          <description>Antibody concentrations against RV were determined as GMCs and expressed as U/mL. The analysis was assessed to demonstrate the immunogenicity of the PCV-free liquid HRV vaccine (individual HRV liquid groups) to that of the currently licensed lyophilised HRV vaccine in terms of serum anti-RV IgA antibody concentrations 1-2 months after Dose 2.</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="326"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.7" lower_limit="125.6" upper_limit="193.1"/>
                    <measurement group_id="O2" value="147.3" lower_limit="118.4" upper_limit="183.3"/>
                    <measurement group_id="O3" value="175.9" lower_limit="142.8" upper_limit="216.8"/>
                    <measurement group_id="O4" value="153.8" lower_limit="125.1" upper_limit="189.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Anti-RV IgA Concentrations (Pooled HRV Liquid Group)</title>
        <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the pooled HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunogenicity of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL, 1-2 months after Dose 2</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_Pool Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of pooled lot A, B and C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Anti-RV IgA Concentrations (Pooled HRV Liquid Group)</title>
          <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the pooled HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
For this outcome measure, the three groups (Liq_A, Liq_B &amp; Liq_C) were pooled into a single group (Liq_Pool group) as they all received PCV free-liquid HRV vaccine, and as pre-specified in the protocol, the immunogenicity of the Liq_Pool group was compared to the currently licensed lyophilized HRV vaccine (Lyo_Control group) in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL, 1-2 months after Dose 2</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="59.9" upper_limit="66.0"/>
                    <measurement group_id="O2" value="62.3" lower_limit="56.8" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Anti-RV IgA Concentrations (Individual HRV Liquid Groups)</title>
        <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the individual HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. The analysis was performed to assess the immunogenicity of the PCV-free liquid HRV vaccine (pooled HRV liquid groups) and the currently licensed lyophilised HRV vaccine, in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL 1-2 months after Dose 2.</description>
        <time_frame>At Month 2-4 (i.e. approximately 1-month or 2-months after second dose of HRV vaccine according to the immunisation schedule for RV vaccine administration in participating countries)</time_frame>
        <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Anti-RV IgA Concentrations (Individual HRV Liquid Groups)</title>
          <description>Antibody concentrations ≥90 U/mL were determined and expressed as GMCs, assessed for the individual HRV liquid groups and Control Group. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations. The analysis was performed to assess the immunogenicity of the PCV-free liquid HRV vaccine (pooled HRV liquid groups) and the currently licensed lyophilised HRV vaccine, in terms of percentage of subjects with anti-RV IgA antibody concentrations ≥ 90 U/mL 1-2 months after Dose 2.</description>
          <population>The analysis was performed on the PPS for immunogenicity that included all subjects who received both doses of study vaccine and for whom the liquid HRV vaccine or control vaccine was administered according to protocol and for whom immunogenicity data were available at the post-vaccination sampling time point.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="326"/>
                <count group_id="O3" value="326"/>
                <count group_id="O4" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="57.2" upper_limit="67.9"/>
                    <measurement group_id="O2" value="61.0" lower_limit="55.5" upper_limit="66.4"/>
                    <measurement group_id="O3" value="65.3" lower_limit="59.9" upper_limit="70.5"/>
                    <measurement group_id="O4" value="62.3" lower_limit="56.8" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Solicited General Adverse Events (AEs).</title>
        <description>Assessed solicited general AEs were cough/runny nose, diarrhea, fever (defined as temperature ≥ 38.0°C), irritability/fussiness, loss of appetite and vomiting. Any solicited general AE is defined as any occurrence of the specified symptom, irrespective of intensity grade and relationship to vaccination.</description>
        <time_frame>During the 8 days (Day 1 to Day 8) follow-up period after each dose of HRV vaccine</time_frame>
        <population>Analysis was performed on the Exposed Set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Solicited General Adverse Events (AEs).</title>
          <description>Assessed solicited general AEs were cough/runny nose, diarrhea, fever (defined as temperature ≥ 38.0°C), irritability/fussiness, loss of appetite and vomiting. Any solicited general AE is defined as any occurrence of the specified symptom, irrespective of intensity grade and relationship to vaccination.</description>
          <population>Analysis was performed on the Exposed Set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any - Cough / Runny Nose - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Cough / Runny Nose - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Diarrhea - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Diarrhea - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Fever (≥ 38.0°C) - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Fever (≥ 38.0°C) - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Irritability / Fussiness - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="214"/>
                    <measurement group_id="O3" value="209"/>
                    <measurement group_id="O4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Irritability / Fussiness - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="194"/>
                    <measurement group_id="O4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Loss of appetite - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Loss of appetite - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Vomiting - Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="402"/>
                    <count group_id="O4" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any - Vomiting - Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="396"/>
                    <count group_id="O3" value="392"/>
                    <count group_id="O4" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Unsolicited AEs.</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination.</description>
        <time_frame>During the 31 day (Day 1 to Day 31) follow-up period after HRV vaccination across doses</time_frame>
        <population>Analysis was performed on the Exposed set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Unsolicited AEs.</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination.</description>
          <population>Analysis was performed on the Exposed set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="200"/>
                    <measurement group_id="O4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.</description>
        <time_frame>During the entire study period (Day 1 to Month 7-8)</time_frame>
        <population>Analysis was performed on the Exposed set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liq_A Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O2">
            <title>Liq_B Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O3">
            <title>Liq_C Group</title>
            <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
          </group>
          <group group_id="O4">
            <title>Lyo Control Group</title>
            <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.</description>
          <population>Analysis was performed on the Exposed set (ES). The ES included all subjects with at least one study vaccine administration documented. A safety analysis based on the ES included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="400"/>
                <count group_id="O2" value="396"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs: During the 8 days (Day 1 to Day 8) follow-up period after each vaccination. Unsolicited AEs: During the 31 days (Day 1 to Day 31) follow-up period after vaccination. SAEs: Throughout the study period (Day 1 to Month 7-8).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liq_A Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot A at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="E2">
          <title>Liq_B Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot B at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="E3">
          <title>Liq_C Group</title>
          <description>Subjects who received two doses of PCV-free HRV liquid formulation of lot C at 6 and 12 weeks of age.</description>
        </group>
        <group group_id="E4">
          <title>Lyo Control Group</title>
          <description>Subjects who received two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Encephalitis enteroviral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Meningitis haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Infantile spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Subdural hygroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="333" subjects_at_risk="400"/>
                <counts group_id="E2" subjects_affected="242" subjects_at_risk="396"/>
                <counts group_id="E3" subjects_affected="338" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="338" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ankyloglossia congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Brachycephaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Craniosynostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gray matter heterotopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Plagiocephaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="402"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="400"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="396"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="57" subjects_affected="38" subjects_at_risk="400"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="396"/>
                <counts group_id="E3" events="45" subjects_affected="31" subjects_at_risk="402"/>
                <counts group_id="E4" events="59" subjects_affected="44" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="400"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Mucous stools</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Post-tussive vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="400"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="396"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="402"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vaccination site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Immunisation reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Anal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="400"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="396"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="402"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="400"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="402"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="400"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="402"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="400"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="396"/>
                <counts group_id="E3" events="40" subjects_affected="36" subjects_at_risk="402"/>
                <counts group_id="E4" events="37" subjects_affected="29" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="396"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="402"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Subglottic laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="400"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="396"/>
                <counts group_id="E3" events="36" subjects_affected="31" subjects_at_risk="402"/>
                <counts group_id="E4" events="32" subjects_affected="30" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="192" subjects_affected="145" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="177" subjects_affected="139" subjects_at_risk="402"/>
                <counts group_id="E4" events="191" subjects_affected="141" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Feeding disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Poor feeding infant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Underweight</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired plagiocephaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Head deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Drooling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="426" subjects_affected="276" subjects_at_risk="400"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="396"/>
                <counts group_id="E3" events="408" subjects_affected="264" subjects_at_risk="402"/>
                <counts group_id="E4" events="419" subjects_affected="261" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Merycism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Selective eating disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Crystalluria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Penile adhesion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="213" subjects_affected="165" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="198" subjects_affected="152" subjects_at_risk="402"/>
                <counts group_id="E4" events="214" subjects_affected="163" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne infantile</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Asteatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="402"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="402"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="400"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="396"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="402"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="402"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Mechanical urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Perioral dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="400"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="396"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="400"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="396"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

